Introduction
============

The mortality of cervical cancer has decreased since cervical cancer screening tests, such as Papanicolaou smear, were introduced, but it remains a significant cause of death \[[@b1-crt-2014-206],[@b2-crt-2014-206]\]. About 7,000-15,000 new patients are diagnosed with cervical cancer every year and 4,600-6,800 patients die of cervical cancer every year worldwide \[[@b2-crt-2014-206]-[@b4-crt-2014-206]\]. About 10%-20% of patients develop recurrent disease after primary treatment. The treatment of recurrent disease may differ by the site of recurrence, prior treatment, and degree of recurrence \[[@b1-crt-2014-206]\]. The lung is commonly affected by hematogenous spread, often detected as a solitary pulmonary nodule or multiple metastases. Especially in cases of a solitary pulmonary nodule, it is important to discriminate between pulmonary metastasis, primary lung cancer, and carcinoid tumors \[[@b5-crt-2014-206]\].

The literature has led many investigators to focus on surgery upon a solitary pulmonary nodule and its outcome. However, multiple pulmonary metastases are frequent. In this study, we reviewed the medical records of cervical cancer patients who were diagnosed with lung metastases (solitary or multiple) during or after primary treatment and analyzed their clinicopathological characteristics.

Materials and Methods
=====================

We analyzed 56 patients with cervical cancer who were treated with radical hysterectomy, concurrent chemoradiation, or combination chemotherapy, and developed pulmonary metastases during or after primary treatment between January 1990 and March 2014. Clinicopathological data was collected from their medical records. The records include demographic characteristics, the initial stage, symptoms at the diagnosis of pulmonary metastasis, event-free duration (EFD), and survival time. This study was approved by the Institutional Review Board (KC14RISI0487). All statistical analyses were done using the Wilcoxon sign rank, chi-square, log-rank, and ANOVA tests. SPSS ver. 22.0 (IBM Co., Armonk, NY) was used for all statistical analyses.

Results
=======

The median age was 55 years, with a range of 36 to 61 years. Ten patients (17.9%) were at stage I (4 patients were at stage Ib1 and 6 patients were at stage Ib2), 29 patients (51.8%) at stage II, six patients (10.1%) at stage III, 10 patients (17.9%) at stage IV, and one patient's (1.8%) stage was unknown. Patients at stage Ib1 were observed further without any additional treatment. Of the six patients at stage Ib2, four underwent concurrent chemoradiation therapy (CCRT) for lymph node metastasis and two with suspicious lymphatic invasion who refused treatment were tracked for outcomes. The remaining patients underwent operation, CCRT, or chemotherapy depending on tumor stage. Forty-two patients out of the 56 underwent primary or postoperative CCRT. CCRT was cisplatin-based (40 mg/m^2^ at 7-day intervals). Forty-six patients, excluding patients at stage I, underwent combination chemotherapy every 3 weeks as a primary treatment or after CCRT depending on tumor stage: carboplatin (300 mg/m^2^)+VP16 (100 mg/m^2^), carboplatin (area under the curve 5-6 mg/m^2^)+paclitaxel (175 mg/m^2^), or cisplatin (50 mg/m^2^)+5-fluorouracil (1,000 mg/m^2^). When lung metastasis was suspected during exam at the outpatient clinic, immunohistochemistry staining of the resected or biopsied specimens for cytokeratin 7, CD56a, chromogranin, thyroid transcription factor-1, and p16 were conducted to rule out primary lung cancer. Based on the immunohistochemical staining results, specimens that were diffusely stained and strongly positive for p16 diffuse and strong positive were included in the study. We excluded specimens that were focally stained and weakly positive for p16. [Table 1](#t1-crt-2014-206){ref-type="table"} shows the characteristics of the study subjects. Although a significant portion of the patients (40 patients, 71.4%) did not have pulmonary symptoms at recurrence, their pulmonary recurrence or metastasis was incidentally detected by chest X-ray or pelvic computed tomography (CT). Four patients (7.1%) complained of dyspnea, four patients (7.1%) of general ache or weakness, and eight patients (14.4%) of dry cough. The histological findings of primary cervical cancer showed 45 patients with squamous cell carcinoma (SCC), seven patients with adenocarcinoma, three patients with adenosquamous cell carcinoma, and one patient with small cell carcinoma. The pulmonary lesions were noticed in the right lung (n=10, 17.9%), the left lung (n=5, 8.9%), and both lungs (n=37, 66.1%). However, four patients (7.1%) had malignant pleural effusion without parenchymal involvement. Twelve patients underwent complete removal of lung metastasis: six had one metastatic nodule, four had two metastatic nodules, and two had three metastatic nodules. Of the remaining 44 patients, four with malignant pleural effusion underwent paracentesis to relieve dyspnea, and 40 underwent biopsy (bronchoscopic biopsy, CT guided biopsy, open lung biopsy) because the pulmonary metastatic lesions were small and multiple. The mean EFD (duration from the diagnosis of initial cervical cancer to lung metastasis) was 12 months. [Table 2](#t2-crt-2014-206){ref-type="table"} shows EFD and overall survival (OS) by various factors. EFD did not differ significantly by initial stage, but OS decreased by initial stage (p \< 0.001). The survival curve using the log-rank test was similar (p=0.001) ([Fig. 1](#f1-crt-2014-206){ref-type="fig"}). OS and EFD did not differ significantly by histologic type (p=0.141 and p=0.234, respectively) ([Table 2](#t2-crt-2014-206){ref-type="table"}, [Fig. 2](#f2-crt-2014-206){ref-type="fig"}).

Our 52 patients received platinum-based chemotherapy after pulmonary lesions were resected or pulmonary metastases were diagnosed by radiologic imaging studies. Of patients diagnosed with pulmonary metastases, four refused additional treatment. OS and EFD were longer in patients treated with platinum-based chemotherapy.

The number of pulmonary lesions at diagnosis on chest CT was significantly associated with OS and EFD. Twenty-two patients, including three patients with malignant pleural effusion, had 0 to 3 nodules in the chest by CT. Thirty-four patients showed multiple variable-sized nodules. OS and EFD were longer in patients with ≤ 3 nodules than in those with \> 4 nodules (p=0.034 and p=0.045 , respectively). Of 22 patients who had ≤ 3 nodules, 12 were treated with surgical resection (10 patients, mass excision; 2 patients, lobectomy). Three patients were treated with drainage of pleural effusion and pleurodesis. No surgical treatment was conducted on seven patients: two with the lesions in the hilar area, in one with a poor general condition and low operability, and in four with extrapulmonary metastatic lesions. OS was longer in patients who were treated with surgical resection than in those who were not (p=0.006).

Discussion
==========

Pulmonary metastasis occurs in a small number of patients with cervical cancer. The prevalence of pulmonary metastasis was 2.1%-6.1% \[[@b2-crt-2014-206],[@b6-crt-2014-206]-[@b8-crt-2014-206]\]. The relationship between the incidence of pulmonary metastasis and the initial stage is extremely weak. In our study, 17.9% of the patients were at stage I, 51.8% at stage II, 10.1% at stage III, 17.9% at stage IV, and 1.8% at an unknown stage. Recurrence occurred most frequently in patients at stage II and decreased in those at stages III and IV. Barter et al. \[[@b2-crt-2014-206]\] also reported that pulmonary metastasis is not associated with the initial stage. By their report, 36% of the patients were at stage I, 33% at stage II, 11% at stage III, and 15% at stage IV. In contrast, Imachi et al. \[[@b6-crt-2014-206]\] demonstrated that the incidence of pulmonary metastasis is high when the initial stage is advanced and that the size of primary cancer is related to the incidence of pulmonary metastasis.

In our study most patients did not complain of pulmonary symptoms. Pulmonary lesions were detected on routine follow-up chest X-ray or pelvic CT. The mean EFD was 12 months. In previous studies, the mean EFD was 24 months \[[@b9-crt-2014-206],[@b10-crt-2014-206]\]. Since many patients with pulmonary metastasis have no specific symptoms, they should receive regular and long-term chest exams \[[@b11-crt-2014-206]\]. Serological tumor markers, such as SCC and carcinoembryonic antigen (CEA), can detect tumor recurrence. Rose et al. \[[@b12-crt-2014-206]\] and Ngan et al. \[[@b13-crt-2014-206]\] indicated that SCC levels are higher in the squamous cell tumors than in the non-squamous cell tumors and decreased after treatment. In our study, we investigated the association between tumor markers at the diagnosis of metastasis and survival, using the Spearman correlation coefficient, suggesting that as SCC or CEA levels are increased, OS becomes shorter (p=0.008 and p=0.006, respectively).

In this study, metastatic lesions were treated with surgical resection, chemotherapy or radiation. The decision to perform surgery should be based on the location and number of metastatic lesions, and general condition. Many investigators treat metastatic lesions with resection and adjuvant chemotherapy, especially for a solitary pulmonary nodule \[[@b1-crt-2014-206],[@b7-crt-2014-206],[@b14-crt-2014-206]-[@b16-crt-2014-206]\]. Their criteria for surgical treatment include the following: (1) complete removal or control of primary lesions, (2) no evidence of extrapulmonary lesions, (3) patient tolerance of surgery, (4) sufficient pulmonary reserve after resection, and (5) no treatment better than surgery \[[@b1-crt-2014-206],[@b14-crt-2014-206]-[@b17-crt-2014-206]\]. In our study, 21.4% of all patients underwent operation (17.9% mass excision, 3.5% lobectomy). The mean number of the resected lesions was 1.8, the mean size was 3.3 cm, and negative resection margins were observed in all patients.

When pulmonary nodules are found on chest X-ray or CT, it is important to discriminate between primary and metastatic lesions. Discrimination between primary pulmonary SCC and metastatic pulmonary SCC from the cervix is important in therapeutic strategy for SCC \[[@b4-crt-2014-206]\]. To differentiate between primary pulmonary SCC and lung metastatic pulmonary SCC from the cervix, p16 immunohistochemical staining can be used. The marker p16 is a member of the INK4a family and acts as a cyclin dependent inhibitor. It maintains the tumor suppressor activity of pRb. Human papillomavirus (HPV) infection changes cell cycle regulation through degradation of pRb and causes the development of carcinoma. It rarely occurs in primary pulmonary SCC \[[@b4-crt-2014-206]\]. Wang et al. \[[@b4-crt-2014-206]\] reported that immunohistochemical staining was positive for p16 in 98% of patients with metastatic pulmonary SCC from cervix, which was diffusely and strongly stained. However, in 21% of patients with primary pulmonary SCC, immunohistochemical staining was also positive for p16, which was focally or weakly stained. Plaza et al. \[[@b3-crt-2014-206]\] distinguished these disease entities using reverse transcription *in situ* polymerase chain reaction to detect HPV. In our study, we also used immunohistochemical staining for p16. Pulmonary metastasis is related to prognostic factors, including EFD, the number of lung masses, radiographic patterns of pulmonary metastasis, and cell types ([Table 3](#t3-crt-2014-206){ref-type="table"}). Yamamoto et al. \[[@b1-crt-2014-206]\] and Barter et al. \[[@b2-crt-2014-206]\] indicate that EFD does not influence survival. In contrast, Fuller et al. \[[@b16-crt-2014-206]\] report that longer EFD (\> 36 months) is associated with good prognosis. Anderson et al. \[[@b7-crt-2014-206]\] observe that long EFD (\> 12 months) is associated with good prognosis. In our study, OS was more prolonged in patients with longer EFD. In particular, OS abruptly increased after EFD reached 24 months ([Fig. 3](#f3-crt-2014-206){ref-type="fig"}). The number of resected lung masses does not influence prognosis \[[@b14-crt-2014-206],[@b18-crt-2014-206]\]. Girard et al. \[[@b19-crt-2014-206]\] report that the number of resection mass does not influence prognosis, whereas resectability of pulmonary masses is associated with a good prognosis. In our study, OS was significantly longer in patients treated with surgical resection than in those who were not ([Fig. 4](#f4-crt-2014-206){ref-type="fig"}). Radiographic patterns of pulmonary metastasis influence prognosis. Barter et al. \[[@b2-crt-2014-206]\] suggest that the right lung is involved more frequently than the left lung and that mediastinal and hilar involvements lead to poorer prognosis than parenchymal involvement. Cell types influence prognosis. Yamamoto et al. \[[@b1-crt-2014-206]\] report that SCC shows a better prognosis than non-SCC, such as adenocarcinoma and adenosquamous cell carcinoma. Imachi et al. \[[@b6-crt-2014-206]\] also report that the incidence of pulmonary metastasis and positivity in peritoneal cytology are higher in the adenocarcinoma group than in the SCC group. In our study, however, OS and EFD did not differ significantly by the histologic type. The reason for this may be that the number of non-squamous cell tumor cases was smaller than that of squamous cell tumor cases.

Many clinicians are currently treating patients with pulmonary metastasis using platinum. Response rates to platinum-based chemotherapy are reported to be 26%-67.7% \[[@b2-crt-2014-206],[@b20-crt-2014-206]\]. The response rates to cytoxan and adriamycin are reported to be 65% and 16%-40%, respectively \[[@b2-crt-2014-206],[@b8-crt-2014-206],[@b21-crt-2014-206]\]. In our study, patients were treated with platinum-based combination chemotherapy, with a response rate of 69.6%.

Conclusion
==========

Although hematogenous spread of primary tumors more often occurs in the lung rather than the brain and liver, pulmonary metastases from cervical cancer is rare. Patients with pulmonary metastases often present nonspecific symptoms and sometimes no symptoms. We reviewed the medical records of patients with cervical cancer with pulmonary metastases during or after treatment and analyzed clinical and histopathological characteristics. This study is limited by its retrospective design. Further studies with a variable design are warranted.
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![Overall survival decreases by the initial stage in pulmonary metastasis (p=0.001, the log-rank test).](crt-2014-206f1){#f1-crt-2014-206}

![Overall survival by the histologic type. There is no significant difference between squamous cell and non-squamous cell type (log-rank test, p=0.2).](crt-2014-206f2){#f2-crt-2014-206}

![The relationship between event-free duration (EFD) and overall survival. Overall survival becomes longer with increasing EFD. Overall survival increases abruptly after EFD reaches 24 months (p=0.019).](crt-2014-206f3){#f3-crt-2014-206}

![Overall survival by resectability. The resection group has better overall survival than the non-resection group (log-rank test, p=0.025).](crt-2014-206f4){#f4-crt-2014-206}

###### 

Patient characteristics

  Characteristic                                    No. of patients
  ------------------------------------------------- -----------------
  Histology                                         
   Squamous cell carcinoma                          45
   Adenocarcinoma                                   7
   Adenosquamous cell carcinoma                     3
   Small cell carcinoma                             1
  Event-free duration (mo)                          
   0                                                6
   1-12                                             23
   13-24                                            18
   ≥ 25                                             9
  No. of resections                                 
   0                                                44
   1                                                6
   2                                                4
   3                                                2
  Site of metastasis                                
   Right                                            10
   Left                                             5
   Both (multiple)                                  37
   Malignant effusion                               4
  Symptom when the pulmonary metastasis was noted   
   Incidentally found                               40
   Cough                                            4
   Chest discomfort                                 4
   Dyspnea                                          8

###### 

Overall survival and event-free duration

  Factor                                                No.   Overall survival (95% CI, mo)   p-value    Event-free duration (95% CI, mo)   p-value
  ----------------------------------------------------- ----- ------------------------------- ---------- ---------------------------------- ---------
  Stage                                                                                                                                     
   I                                                    10    56.3 (33-96)                    \< 0.001   18.1 (10.2-32)                     0.297
   II                                                   29    32.9 (24.6-43.9)                           12.6 (9.7-16.3)                    
   III                                                  6     16.2 (10.4-25.2)                           12.2 (9-16.6)                      
   IV                                                   10    18.8 (8.8-40.4)                            20.7 (9.5-44.7)                    
  Histology                                                                                                                                 
   Squamous cell                                        45    28 (21.4-36.5)                  0.141      13.3 (10.7-16.5)                   0.234
   Adenocarcinoma                                       7     57.8 (39.2-85.3)                           21.9 (12.1-39.7)                   
   Other                                                4     29.7 (15.6-56.5)                           13.8 (6.3-30.5)                    
  Adjuvant chemotherapy after diagnosis                                                                                                     
   Yes                                                  52    32.6 (25.8-41.2)                0.027      15.2 (12.8-18.2)                   0.006
   No                                                   4     12.5 (6.6-23.7)                            6 (1.4-26.5)                       
  Detection number of metastatic pulmonary lesion                                                                                           
   0-3[^a)^](#tfn1-crt-2014-206){ref-type="table-fn"}   22    40.7 (27.7-60.0)                0.035      17.6 (12.9-24.2)                   0.045
   ≥ 4                                                  34    25 (19-33)                                 12.1 (9.6-15.2)                    
  Surgical resection                                                                                                                        
   Yes                                                  12    53.8 (32.8-88.4)                0.006      17.2 (12.9-22.9)                   0.255
   No                                                   44    25.9 (20.3-33.2)                           13.3 (10.5-16.8)                   

Calculated by univariate analysis. A p-value of \< 0.05 is statistically significant.

0 means the patient had malignant pleural effusion without parenchymal invasion.

###### 

Survival and important prognostic factors from the literature

  Source                                            No. of patients         Initial stage   Survival                                                 Important prognostic factors
  ------------------------------------------------- ----------------------- --------------- -------------------------------------------------------- -------------------------------
  Yamamoto et al. \[[@b1-crt-2014-206]\]            7,748                   Ib-II           32.9% [^a)^](#tfn2-crt-2014-206){ref-type="table-fn"}    Histologic type
  Age                                                                                                                                                
  Number of metastasis                                                                                                                               
  Barter et al. \[[@b2-crt-2014-206]\]              88                      I-IV            2.3%[^a)^](#tfn2-crt-2014-206){ref-type="table-fn"}      Platinum-based chemotherapy
  Anraku et al. \[[@b14-crt-2014-206]\]             71 (cervical cancer)                    54.6%[^a)^](#tfn2-crt-2014-206){ref-type="table-fn"}     Resectability of lung lesions
  62 (uterine body cancer)                          Disease free interval                                                                            
  Fuller et al. \[[@b16-crt-2014-206]\]             15                      I-IV            36%[^a)^](#tfn2-crt-2014-206){ref-type="table-fn"}       Event-free duration
  Resectability of lung lesions                                                                                                                      
  Shiromizu et al. \[[@b11-crt-2014-206]\]          519                     Ib-IIb          36%[^a)^](#tfn2-crt-2014-206){ref-type="table-fn"}       Platinum-based chemotherapy
  Tumor marker                                                                                                                                       
  Resectability of lung lesions                                                                                                                      
  Present study                                     56                      I-IV            32.8 mo[^b)^](#tfn3-crt-2014-206){ref-type="table-fn"}   Adjuvant chemotherapy
  Detection number of pulmonary metastatic lesion                                                                                                    
  Resectability of lung lesions                                                                                                                      

5-Year survival,

Overall survival.
